Kasey Leger, MD, MSc is a pediatric oncologist at Seattle Children’s Hospital and Associate Professor at the University of Washington. Dr. Leger’s clinical and research interests focus on hematologic malignancies and cancer therapy associated cardiotoxicity. Dr. Leger leads the Children’s Oncology Group (COG) Myeloid Cardiotoxicity Working Group and the cardiac correlative studies embedded in the ongoing COG phase III randomized trial of CPX-351 in children with de novo acute myeloid leukemia (AML). Additionally, she is the principal investigator of the Seattle Children’s Cardiotoxicity Cohort Study assessing novel blood and imaging-based markers of cardiotoxicity. Dr. Leger’s overarching research goals are to reduce the toxicity of cancer therapy through primary cardioprotective interventions and identify validated risk predictors to guide secondary cardioprotection and ultimately contribute to long-term cancer cure without the burden of life-threatening heart disease during survivorship.